132 related articles for article (PubMed ID: 30110005)
1. [Clinical features and prognosis for anaplastic large cell lymphoma].
Dong F; Liu Y; Li Q; Wang J; Jing H; Ke X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 43(6):631-637. PubMed ID: 30110005
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
Chen YK; Yu WJ; Liu H; Wei JY; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):222-227. PubMed ID: 32311892
[No Abstract] [Full Text] [Related]
3. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic large cell lymphoma: a single institution experience from India.
Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L
J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
[TBL] [Abstract][Full Text] [Related]
7. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology.
Brugières L; Deley MC; Pacquement H; Meguerian-Bedoyan Z; Terrier-Lacombe MJ; Robert A; Pondarré C; Leverger G; Devalck C; Rodary C; Delsol G; Hartmann O
Blood; 1998 Nov; 92(10):3591-8. PubMed ID: 9808552
[TBL] [Abstract][Full Text] [Related]
8. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Isogai R; Fukao M; Kawada A
J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI
Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N; Trümper L; Ziepert M; Nickelsen M; Ho AD; Metzner B; Peter N; Loeffler M; Rosenwald A; Pfreundschuh M
Blood; 2010 Nov; 116(18):3418-25. PubMed ID: 20660290
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
14. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
16. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ
Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022
[No Abstract] [Full Text] [Related]
17. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
18. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
Sibon D; Fournier M; Brière J; Lamant L; Haioun C; Coiffier B; Bologna S; Morel P; Gabarre J; Hermine O; Sonet A; Gisselbrecht C; Delsol G; Gaulard P; Tilly H
J Clin Oncol; 2012 Nov; 30(32):3939-46. PubMed ID: 23045585
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
